menu
    • menu
    [{"orgOrder":0,"company":"Dr. Reddy\\'s Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch Of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Market","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Lansoprazole","moa":"Potassium-transporting ATPase","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Dr. Reddy\\\\\\'s Laboratories","amount2":0,"therapeuticAreaNew":"Gastroenterology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Delayed-Release Orally Disintegrating Tablet","sponsorNew":"Dr. Reddy\\\\\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\.."},{"orgOrder":0,"company":"NHS England","sponsor":"University of Manchester","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aspirin to be Trialled as Part of New Treatment for Aggressive Form of Breast Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Aspirin","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"NHS England","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"NHS England \/ University of Manchester","highestDevelopmentStatusID":"8","companyTruncated":"NHS Englan.."}]

    Find Clinical Drug Pipeline Developments & Deals for PREVACID NAPRAPAC 250 (COPACKAGED)

    Menu

    PREVACID NAPRAPAC 250 (COPACKAGED)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy\'s Laboratories

                            India arrow
                            CPhI Worldwide, Milan
                            Booth #24A41
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Lansoprazole

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories Announces the Launch Of Lansoprazole DR Orally Disintegrating Tablets in the U.S. Mar...

                            Details : The Prevacid® brand and generic had U.S. sales of approximately $87 million MAT for the most recent twelve months ending in December 2020 according to IMS Health*.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 22, 2021

                            Lead Product(s) : Lansoprazole

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NHS England

                            United Kingdom arrow
                            Formnext Forum
                            Not Confirmed

                            NHS England

                            United Kingdom arrow
                            Formnext Forum
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aspirin,Avelumab,Lansoprazole

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : University of Manchester

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Aspirin to be Trialled as Part of New Treatment for Aggressive Form of Breast Cancer

                            Details : Breast Cancer Now said successful results could lead to further clinical trials of aspirin and avelumab for incurable secondary triple negative breast cancer, which happens when cancer cells that started in the breast spread to other parts of the body.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 18, 2021

                            Lead Product(s) : Aspirin,Avelumab,Lansoprazole

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : University of Manchester

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth